Welcome to this month’s ADVOCATE BRIEF
Four mechanisms moved in the same month, and every one of them decides whether a patient reaches treatment. A peer-reviewed study on what happens after a pharmacy rejects a prescription. A cost analysis showing one drug carrying three prices. A federal comment file that closed with almost no patient voice inside it. An employer market rebuilding the pharmacy benefit in real time. Here is what happened, and here is what the organizations building the commercial case for patient-centered healthcare should do about it.
Researchers at Johns Hopkins and AEI found that 32 percent of first attempts to fill a single-source brand drug get rejected on formulary grounds, and 48.4 percent of those rejections end in no fill at all. Health Affairs put markups on one infused biologic at 173 percent, 78 percent, and 16 percent depending on the site of care. CMS closed the comment period on the permanent Medicare negotiation rules on August 17 with biopharma, hospitals, and oncology groups all filing heavily. KFF read the 2027 rate filings and found insurers seeking a median 15 percent increase.
I have spent more than two decades watching this industry write the rules that govern access and then explain them to patients afterward. August ran that pattern at full speed. Every technical fight resolved into the two questions a patient actually asks, which are whether the drug arrives and what it costs, and almost nobody put those two questions on the record.
Four storylines ran through August, and they share one mechanism. Institutions negotiate with each other over money, and the patient inherits whatever the negotiation produces. Organizations that want a different outcome need to be in the room while the language is still in draft, not after the rule publishes.
CMS closed the comment period on the permanent Medicare Drug Price Negotiation Program rules on August 17 under CMS-4215-P.
Hannah Garden-Monheit published a paper calling for a statutory ban on prior authorization as insurers practice it.
HRSA advanced its revised 340B Rebate Model Pilot over sustained hospital objection.
The Senate HELP Committee advanced a 35 dollar monthly insulin cap for privately insured patients by a vote of 17 to 5.
Researchers at Johns Hopkins and AEI reviewed more than two million first-time fills and found 32 percent of initial attempts for single-source brand drugs rejected on formulary grounds.
Health Affairs analyzed 59,717 patients and found markups over acquisition cost for one infused biologic averaging 173 percent at 340B-eligible hospitals.
KFF read the 2027 rate filings and found ACA Marketplace insurers seeking a median 15 percent increase.
August 2026 proved that access gets decided in dockets, rate filings, and benefit design meetings rather than in press releases. One in three first prescriptions died at the pharmacy counter and half of those were never replaced by anything. One drug carried three prices set by the address on the infusion order.
Originally published in The Archo Advocate Brief.
